Mirubedis (Rivaroxaban)

Rivaroxaban directly inhibits coagulation factor Xa, a key enzyme that converts prothrombin to thrombin. By blocking this step, it reduces thrombin generation and fibrin clot formation, providing anticoagulation without the need for antithrombin activation.

The dose of rivaroxaban is individualized by the prescribing clinician based on the specific indication, renal function, age, and other patient factors. Only a qualified healthcare professional should determine the appropriate regimen.

Safety data for rivaroxaban during pregnancy and lactation are limited. It is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their physician.

To request Mirubedis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with warfarin, rivaroxaban offers fixed dosing without routine INR monitoring and fewer food‑drug interactions. Compared with other direct oral anticoagulants such as apixaban, rivaroxaban has a similar efficacy profile but may differ in dosing frequency and renal clearance considerations.

Mirubedis tablets should be stored at ambient temperature, below 25 °C, in the original blister pack to protect from moisture and light. Keep the container tightly closed and out of reach of children.

Mirubedis is taken orally as a tablet, swallowed whole with water. It can be taken with or without food, according to the prescriber’s instructions, and should be taken at the same time each day to maintain consistent anticoagulation.

The most serious risks include major bleeding events such as gastrointestinal hemorrhage, intracranial bleeding, and spinal or epidural hematoma. Patients should seek immediate medical attention for signs of severe bleeding, sudden weakness, severe headache, or unexplained bruising.

Mirubedis is contraindicated in individuals with active pathological bleeding, severe hepatic disease associated with coagulopathy, or those who have had a recent major surgery with high bleeding risk. It should also be avoided in patients with known hypersensitivity to rivaroxaban or any of its excipients.